Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
GENEREX BIOTECHNOLOGY CORP (GNBT)
|
Add to portfolio |
|
|
|
| Price: |
$0.06
| | Metrics |
| OS: |
118.4
|
M
| |
|
|
| Market cap: |
$6.85
|
M
| |
|
|
|
Net debt:
|
$16.6
|
M
| |
|
|
|
EV:
|
$23.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($30.9)
|
M
| |
|
|
|
EBIT
|
($31.9)
|
M
| |
|
|
| EPS |
($0.46)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jul-31-20 | Jul-31-19 | Jul-31-18 | Jul-31-17 | Jul-31-16 | Jul-31-15 | Jul-31-14 | Jul-31-13 |
| Revenues | 2.7 | 6.2 | 0.7 | 0.0 | 3.1 | 1.2 | 0.0 | 0.0 |
| Revenue growth | -57.1% | 782.2% | | -100.0% | 158.9% | | | -100.0% |
| Cost of goods sold | 0.6 | 4.1 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 |
| Gross profit | 2.1 | 2.1 | 0.7 | 0.0 | 3.1 | 0.0 | 0.0 | 0.0 |
| Gross margin | 78.2% | 33.3% | 100.0% | | 100.0% | 0.0% | | |
| Selling, general and administrative | | | | 1.6 | | | | 0.0 |
| Research and development | 2.1 | 1.7 | 0.8 | | 0.5 | | 1.4 | |
| General and administrative | 17.9 | 21.4 | 2.4 | | 1.4 | 2.4 | 3.0 | 0.0 |
| EBITA | -16.3 | -24.4 | -2.5 | 0.0 | -0.5 | -3.6 | -4.4 | 0.4 |
| EBITA margin | -613.6% | -392.9% | -354.5% | | -14.8% | -300.6% | | |
| Amortization of intangibles | 0.7 | 0.3 | 0.0 | 0.0 | 0.3 | | | 0.4 |
| EBIT | -17.0 | -24.6 | -2.5 | 0.0 | -0.7 | -3.6 | -4.4 | 0.0 |
| EBIT margin | -638.2% | -397.1% | -354.9% | | -24.0% | -300.6% | | |
| Pre-tax income | -34.2 | -11.0 | 35.9 | 0.0 | -3.2 | -2.2 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | |
| Net income | -33.3 | -9.3 | 36.3 | 0.0 | -3.2 | -2.5 | -2.1 | 0.0 |
| Net margin | -1252.5% | -150.6% | 5166.6% | | -105.0% | -213.7% | | |
| |
| Diluted EPS | ($0.46) | ($0.14) | $14.02 | $0.00 | ($3.69) | $0.00 | $0.00 | $0.00 |
| Shares outstanding (diluted) | 73.1 | 67.7 | 2.6 | 1.0 | 0.9 | 793.3 | 679.6 | 386.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|